Annual report pursuant to Section 13 and 15(d)

Balance Sheet Account Details - Contingent Liabilities (Details)

v3.8.0.1
Balance Sheet Account Details - Contingent Liabilities (Details) - USD ($)
12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Business Acquisition [Line Items]      
Revenue royalty payable on all Cydex-related revenue (as a percent)   20.00%  
Cydex-related revenue amount that triggers royalty payments   $ 15,000,000.0  
Additional revenue royalty payable when higher threshold of Cydex-related revenue met (percent)   10.00%  
Cydex-related revenue amount that triggers additional royalty payments   $ 35,000,000.0  
Contingent Liability [Roll Forward]      
Commercial rights at beginning of period $ 8,100,000 13,500,000  
Payments (4,998,000) (8,777,000) $ (6,740,000)
Fair Value Adjustment 2,500,000 3,400,000  
Additions 8,400,000    
Commercial rights at end of period 14,000,000 8,100,000 13,500,000
Cydex      
Contingent Liability [Roll Forward]      
Commercial rights at beginning of period 6,600,000 9,500,000  
Payments (5,000,000) (6,200,000)  
Fair Value Adjustment 0 3,300,000  
Additions 0    
Commercial rights at end of period 1,600,000 6,600,000 9,500,000
Metabasis      
Contingent Liability [Roll Forward]      
Commercial rights at beginning of period 1,500,000 4,000,000  
Payments 0 (2,600,000)  
Fair Value Adjustment 2,500,000 100,000  
Additions 0    
Commercial rights at end of period 4,000,000 1,500,000 4,000,000
Crystal      
Contingent Liability [Roll Forward]      
Commercial rights at beginning of period 0 0  
Payments 0 0  
Fair Value Adjustment 0 0  
Additions 8,400,000    
Commercial rights at end of period $ 8,400,000 $ 0 $ 0